<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Inst for Cell and Molecular Biosciences</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D798EA3C-8D07-4F4C-AF64-5131B1354980"><gtr:id>D798EA3C-8D07-4F4C-AF64-5131B1354980</gtr:id><gtr:name>Technostics Ltd</gtr:name><gtr:address><gtr:line1>The Deep Business Centre</gtr:line1><gtr:line2>Tower Street</gtr:line2><gtr:line4>Kingston upon Hull</gtr:line4><gtr:line5>East Yorkshire</gtr:line5><gtr:postCode>HU1 4BG</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A51DC1E1-B67E-4238-89D8-DFA52C626FBF"><gtr:id>A51DC1E1-B67E-4238-89D8-DFA52C626FBF</gtr:id><gtr:firstName>Jeff</gtr:firstName><gtr:surname>Pearson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/351F751A-16D2-440B-82F8-311077803D9B"><gtr:id>351F751A-16D2-440B-82F8-311077803D9B</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Seal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG00563X%2F1"><gtr:id>3C202C91-68DD-4115-8877-2C0600CC0916</gtr:id><gtr:title>Bioactive Alginates and Obesity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/G00563X/1</gtr:grantReference><gtr:abstractText>Obesity is one of the fastest growing medical issues across the western world and it is fast becoming one of the leading causes of mortality worldwide. At least one in thirteen annual deaths in the European Union are likely to be related to overweight. That is 337,000 deaths/year and Britain leads the E.U. table of deaths related to excess body weight. Half the adults in the U.K. are overweight and around one in four is obese. Obesity increases the risk of high blood pressure, heart disease and late onset diabetes with an estimated cost to the economy of &amp;pound;2 Billion/year. In general, women have a greater body mass index (BMI) distribution and higher obesity rate compared to men. Obesity is a condition associated with poverty and a poor diet in both the developed and developing nations. It is therefore particularly important that if treatment/prevention is delivered via diet that the foods should be affordable and acceptable e.g. bread, the vehicle we intend to trial. Because eating is a pleasurable experience and humans tend to over eat if food is available in excess, in particular high energy foods which are often rich in fat. Reducing fat metabolism and uptake is one approach to reducing weight gain. Therefore chemically synthesised inhibitors of the fat digesting enzymes, lipases are currently being used to treat obesity. At present the major lipase inhibitor available on prescription in the U.K. is orlistat (Xenical) which will reduce fat absorption by up to 30%. However side effects such as oily stools, flatulence and diarrhoea have meant reduced acceptability. Interestingly these side effects can be significantly reduced if the lipase inhibitor is taken with a dietary fibre supplement. Therefore a good solution would be a dietary fibre with lipase inhibitory activity. Alginate, a natural fibre from seaweed has these properties. We have demonstrated in our lab that alginates have a similar ability to inhibit lipase as orlistat. We therefore aim to screen abank of alginates (over 20), some of which are already used in the food industry at low levels and other naturally occurring biopolymers to determine the best lipase inhibitor profile using a lab based colorimetric assay. Using the best inhibitors we will demonstrate their ability to inhibit lipase activity in conditions as close as possible to those in the gut, i.e. with other food components etc. The best candidate/s from the above studies will then be tested (delivered in bread in the first instance) in human volunteers. A group of healthy subjects will be used to determine acceptability of the biopolymer in the food vehicle and to determine the best balance between lipase inhibition and levels of biopolymer intake. Our preliminary studies showed no acceptability problems with alginate levels as high as 10% by weight in bread. Following the studies with the healthy subjects the biopolymer enriched foods will be tested to demonstrate calorific intake reduction in ileostomy patients. This study has the potential to provide evidence that normal foods supplemented with fibre biopolymers can be used to treat obesity/overweight and allow this to be translated by the food industry into the development of a range of other tasty and affordable food products. Such a range would have the potential to reduce calorific intake, as well as include the health benefits of dietary fibre.</gtr:abstractText><gtr:technicalSummary>Objective 1: To screen a bank of alginates and other biopolymers for their ability to inhibit gastro-intestinal lipase. Lipase activity will be measured in a colorimetric assay using the synthetic substrate1,2-o-Dilauryl-RAC-glycerol-3-glutaric acid-6'-methylresorufin ester. The mechanism of inhibition will be determined, and as it is likely to be reversible, kinetic studies will determine the class of inhibition. Factors such as viscosity, soluble vs insoluble fractions and calcium binding will be investigated. The information generated will be used to match the best alginate with the structure and composition of naturally occurring alginates or alginate mixtures which are available as food additives with extensive safety data. Objective 2: To test the biopolymers identified from objective 1 in conditions of the digestive tract. This will be achieved by lipase inhibition studies with the synthetic substrate and a tryglyceride substrate in the presence of other nutrients. The lipid substrate +/- the inhibitor is suspended in artificial saliva pH 7-8 containing amylase and agitated for 5min at 37oC. The resulting suspension is mixed 1:3 (saliva: gastric juice, vol/vol) with artificial gastric juice pH 1-2 containing pepsin and agitated at 37oC for 1hour. This is then mixed with artificial pancreatic juice and pig bile in the ratio of 15:6:18 (gastric/saliva mixture: pig bile :pancreatic juice) containing amylase, trypsin and chymotrypsin. At this stage the lipase and co-lipase are added and incubated for 1.5 hours at 37oC. Aliquots will be removed at 10min intervals to measure, using GLC free fatty acids, tri, di and monoacylglycerols and glycerol. Using this methodology optimum alginate: lipase ratios will be determined. Objective 3: To demonstrate efficacy of the inhibitor in vivo. This will be achieved with human volunteer studies including (10) healthy and (40) ileostomy patients using questionaires and lipid determination to quantify calorie reductions.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>398025</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>2010 Press Release and GMTV Appearance</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6CF924D5-6C7A-40BA-B703-7252C38E1EBA</gtr:id><gtr:impact>Press release increased the public awareness of the project and increase the interest from local, national and international companies.

We began to work closer with Greggs Plc.</gtr:impact><gtr:outcomeId>54634bef5959c7.28187362</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbsrc.ac.uk/news/food-security/2010/100322-pr-seaweed-to-tackle-obesity.aspx</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biotechnology YES</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>245AFE72-5D14-4C99-9DDA-B1B81AE4776C</gtr:id><gtr:impact>Inspired post-gradate students and postdocs to look at their own research commercially.

After my talk people have asked for further information about the project as well as my views on their own project.</gtr:impact><gtr:outcomeId>546346b9dee5a2.98052556</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Fat Truth about Low Fat Food</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>495CD299-9FA6-4C88-AC34-EF040D328E03</gtr:id><gtr:impact>We had many request for further information about the project as well as requests to participate in the research

Several large multinational companies have contacted the research team to be kept informed about the progress of the project.</gtr:impact><gtr:outcomeId>546348c07d5866.26430043</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=kodwanogT58</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprise Fellowship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>FF9CAE0C-78A9-4C85-AB5B-3A77325D6DC1</gtr:id><gtr:outcomeId>54633fb5e4de89.18783073</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder Scheme Follow On Fund</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>83D698EF-FFFE-40D3-9F32-348985808BD9</gtr:id><gtr:outcomeId>546342daee69c5.18635093</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprise Fellowship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>5D00CCCC-73A2-4B3B-B413-145A61D19157</gtr:id><gtr:outcomeId>54634094eb4b45.66600917</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The results have been used to form several patents and also taken into another research project.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>51C5EEAB-B167-4F48-B7B8-8D126C04217C</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54638285dcfcf4.49853288</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Certain alginates can inhibit pancreatic lipase. The patent covers the composition of the alginates that best inhibit lipase.</gtr:description><gtr:grantRef>BB/G00563X/1</gtr:grantRef><gtr:id>9829EF5D-7A04-4A3A-818C-2BB457E8549A</gtr:id><gtr:impact>The technology has been shown to reduce the amount of fat absorbed by the body from the diet and increases the amount passing out of the small intestine. Talks are currently ongoing to licence this technology to both large ingredient suppliers as well as large food manufacturers.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5464b93180c3f5.76381133</gtr:outcomeId><gtr:patentId>WO2011/064547A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Inhibition of Pancreatic Lipase</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The consumption of alginate bread reduces the level of triacylglycerol (fat) taken into the blood from the gut and increase the total amount of fat that leaves the small intestine. 
We can mimic the enzymactic and chemical digestion of a human from the mouth to the small intestine.</gtr:description><gtr:exploitationPathways>The findings have formed several patent applications and formed the basis of a pathfinder and follow on fund application. All with the aim of producing a health food to deal with excess calorie intake.</gtr:exploitationPathways><gtr:id>E8BE6B48-853A-49AA-9726-377E17AE623A</gtr:id><gtr:outcomeId>546386e70eaa79.14015575</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.bbsrc.ac.uk/news/health/2013/130228-f-health-by-stealth.aspx</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6E259D5E-B2C8-40CF-A227-D9B235404CEB</gtr:id><gtr:title>Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity.</gtr:title><gtr:parentPublicationTitle>Food hydrocolloids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/849674bc2bfe3e2c104ec8501651cdec"><gtr:id>849674bc2bfe3e2c104ec8501651cdec</gtr:id><gtr:otherNames>Houghton D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0268-005X</gtr:issn><gtr:outcomeId>56d6d034975005.31875945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68FC5540-41EE-438C-B756-9E14B2F78D75</gtr:id><gtr:title>Physiological parameters governing the action of pancreatic lipase.</gtr:title><gtr:parentPublicationTitle>Nutrition research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/467f5d1b66ea615c8aff26919767770b"><gtr:id>467f5d1b66ea615c8aff26919767770b</gtr:id><gtr:otherNames>Brownlee IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0954-4224</gtr:issn><gtr:outcomeId>54633a897bdf62.21388040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54124279-5F7F-463B-B49B-213C785F0C72</gtr:id><gtr:title>The impact of dietary fibres on the physiological processes governing small intestinal digestive processes</gtr:title><gtr:parentPublicationTitle>Bioactive Carbohydrates and Dietary Fibre</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ebb7ddabaf7c56d1cd38edf4610916"><gtr:id>41ebb7ddabaf7c56d1cd38edf4610916</gtr:id><gtr:otherNames>Chater P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d6d3b0525d85.97256808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FB7B826-C80C-4580-A69C-FF9F0FDE42C8</gtr:id><gtr:title>Method for quantifying alginate and determining release from a food vehicle in gastrointestinal digesta.</gtr:title><gtr:parentPublicationTitle>Food chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/849674bc2bfe3e2c104ec8501651cdec"><gtr:id>849674bc2bfe3e2c104ec8501651cdec</gtr:id><gtr:otherNames>Houghton D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0308-8146</gtr:issn><gtr:outcomeId>54633a8a312c34.02169829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8BC3E7A-A6EC-459A-954F-78A6C1AE2C85</gtr:id><gtr:title>The modulation of pancreatic lipase activity by alginates.</gtr:title><gtr:parentPublicationTitle>Food chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4ab2874aeee31c417011e211f41b428"><gtr:id>b4ab2874aeee31c417011e211f41b428</gtr:id><gtr:otherNames>Wilcox MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0308-8146</gtr:issn><gtr:outcomeId>54633a8a076ea1.48764678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C159C6CD-F884-4B01-816F-2529C5D60240</gtr:id><gtr:title>Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.</gtr:title><gtr:parentPublicationTitle>Carbohydrate polymers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f6ecfca9b3ebb40b790b8f4730e5e3e"><gtr:id>3f6ecfca9b3ebb40b790b8f4730e5e3e</gtr:id><gtr:otherNames>Chater PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0144-8617</gtr:issn><gtr:outcomeId>5675e9f868ec8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G00563X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>